In 1907, when Alois Alzheimer first described the clinical and pathologic findings in the case
of 54-year-old Auguste D., her severe and progressive dementia had been grossly obvious …

Objective: To study risk factors for Alzheimer's disease (AD) based on data from the
Canadian Study of Health and Aging. Design: Population-based case-control study. Setting …

Objective: To assess whether the risk of incidence of Alzheimer disease (AD) varies over
time. The increase in numbers of people at the oldest ages in the population will bring an …

Alzheimer disease (AD) is an irreversible neurodegenerative disease of the brain that slowly
destroys memory and the ability to think, eventually debilitating affected patients. A …

With the advent of symptomatic treatment and the prospect of stabilizing therapies for AD,
the race for reliable disease and progression markers has picked up speed. Two hot …

(NIA)–AA group proposed a biological definition of AD stating that if a person had the
biomarker evidence of brain amyloid (A) and tau (T), the pathologic hallmarks of the disease …

When scientists look under the microscope at the brains of very elderly patients who have
died, some confusing patterns are seen. Some patients who had healthy memory and …

CERAD clinical battery. The clinical assessment protocol (table 1) was designed to provide
clinicians with the minimum information necessary to make a confident diagnosis of AD. l …

Objective: To characterize change in depressive symptoms before and after the onset of
dementia in Alzheimer disease (AD). Method: We used data from the Chicago Health and …

These 2 neuropathological hallmarks have been the cornerstone of neuropathological
diagnosis ever since. However, since a few of these lesions are detected in most individuals …